Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

This 8-week, multi-center, open-label study assessed the safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Patients (n=32) with mean sitting systolic blood pressure (msSBP) ⩾140 mm Hg (after a 2–5-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hypertens Res
Hlavní autoři: Ito, Sadayoshi, Satoh, Minoru, Tamaki, Yuko, Gotou, Hiromi, Charney, Alan, Okino, Naoko, Akahori, Mizuki, Zhang, Jack
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396400/
https://ncbi.nlm.nih.gov/pubmed/25693859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/hr.2015.1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky